ArticleRespirology (Carlton, Vic.)2015
Pulmonary manifestations in systemic lupus erythematosus: association with disease activity.
Article in Respirology (Carlton, Vic.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Prevalence and incidence of interstitial lung diseases in systemic lupus erythematosus: systematic review and meta-analyses.Lupus science & medicine · 2026Pooled it
- Systematic review of the reporting of extrarenal manifestations in observational studies of Saudi patients with systemic lupus erythematosus.Lupus science & medicine · 2025Pooled it
- Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial.BMC nephrology · 2018Trial
- Article
- Acute Lupus Pneumonitis: An Uncommon Initial Presentation of Systemic Lupus Erythematosus-A Case Report.Clinical case reports · 2026Article
- Unveiling pleuropulmonary manifestations in systemic lupus erythematosus: a retrospective observational study from the Middle East.Clinical rheumatology · 2026Observational
- Pulmonary Involvement in Systemic Lupus Erythematosus: A Potentially Overlooked Condition.Biomedicines · 2025Review
- Article
- Pleuropulmonary Involvement in Patients with Systemic Lupus Erythematosus as Detected by High-Resolution CT Scans: Clinical and Immunological Association.Medicina (Kaunas, Lithuania) · 2025Article
- Pulmonary Manifestations of Systemic Lupus Erythematosus Among Adults in Aseer Region, Saudi Arabia.International journal of general medicine · 2024Article
- Thoracic manifestations of rheumatic disease: a radiologist's view.Therapeutic advances in musculoskeletal disease · 2024Review
- Article
- Systemic Lupus Erythematosus and Lung Involvement: A Comprehensive Review.Journal of clinical medicine · 2022Review
- Lung Functioning and Inflammation in a Mouse Model of Systemic Juvenile Idiopathic Arthritis.Frontiers in immunology · 2021Article
- Why is a paediatric respiratory specialist integral to the paediatric rheumatology clinic?Breathe (Sheffield, England) · 2020Review
- Thoracic imaging finding of rheumatic diseases.Journal of thoracic disease · 2020Review
- Concomitant new diagnosis of systemic lupus erythematosus and COVID-19 with possible antiphospholipid syndrome. Just a coincidence? A case report and review of intertwining pathophysiology.Clinical rheumatology · 2020Review
- Acute lupus pneumonitis as the initial presentation of systemic lupus erythematosus.BMJ case reports · 2020Article
- Pulmonary Involvement in Children With Systemic Lupus Erythematosus.Frontiers in pediatrics · 2020Article
- Lupus and the Lungs: The Assessment and Management of Pulmonary Manifestations of Systemic Lupus Erythematosus.Frontiers in medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveAlthough systemic lupus erythematosus (SLE) is the most common connective tissue disease affecting the lung, few studies have assessed risk factors that predict pulmonary manifestations. The objectives of the present study were to determine the prevalence of lung manifestations in SLE patients from Western Saudi Arabia by analysing results from high-resolution computed tomography (HRCT) scans and to identify independent risk factors for lung involvement.
methodsThis was a 10-year retrospective study involving 184 SLE patients. We examined all HRCT lung abnormalities and determined whether findings were associated with the presence of lupus nephritis (LN), SLE disease activity (as defined by SLE Disease Activity Index 2000 item scores ≥ 4 for any and all items) or levels of complement and anti-double-stranded DNA (anti-dsDNA).
resultsWe identified 61 patients (33%) with pulmonary involvement, and 52 (85%) of these subjects showed HRCT abnormalities. The most common HRCT findings were pleural effusion, consolidation and atelectasis (58%, 42% and 42%, respectively). There was a significant association between abnormal HRCT results and hypocomplementemia, high levels of anti-dsDNA and disease activity (P < 0.05), particularly with regard to pleuropericardial effusion and consolidation. Pulmonary abnormalities were significantly higher within the first five years after SLE diagnosis (P < 0.001). However, neither disease duration nor LN was associated with increased risk.
conclusionsLung manifestations were frequent in SLE patients from Saudi Arabia, with pleural effusion, consolidation and atelectasis being the most common. Low complement levels, high anti-dsDNA levels and disease activity were significantly associated with abnormal HRCT findings (all P < 0.001).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.